Last reviewed · How we verify

ATG+mycophénolate mofétil+tacrolimus

University Hospital, Toulouse · FDA-approved active Small molecule

ATG+mycophénolate mofétil+tacrolimus is a Immunosuppressive combination therapy Small molecule drug developed by University Hospital, Toulouse. It is currently FDA-approved for Prevention of acute organ rejection in solid organ transplantation, Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation. Also known as: Mycophénolate mofétil = Cellcept.

This combination suppresses the immune system through multiple pathways to prevent organ rejection after transplantation.

This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in solid organ transplantation, Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.

At a glance

Generic nameATG+mycophénolate mofétil+tacrolimus
Also known asMycophénolate mofétil = Cellcept
SponsorUniversity Hospital, Toulouse
Drug classImmunosuppressive combination therapy
TargetT lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

ATG (antithymocyte globulin) depletes T lymphocytes; tacrolimus inhibits calcineurin to block T-cell activation and cytokine production; mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to suppress B and T lymphocyte proliferation. Together, these agents provide synergistic immunosuppression for transplant rejection prevention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ATG+mycophénolate mofétil+tacrolimus

What is ATG+mycophénolate mofétil+tacrolimus?

ATG+mycophénolate mofétil+tacrolimus is a Immunosuppressive combination therapy drug developed by University Hospital, Toulouse, indicated for Prevention of acute organ rejection in solid organ transplantation, Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.

How does ATG+mycophénolate mofétil+tacrolimus work?

This combination suppresses the immune system through multiple pathways to prevent organ rejection after transplantation.

What is ATG+mycophénolate mofétil+tacrolimus used for?

ATG+mycophénolate mofétil+tacrolimus is indicated for Prevention of acute organ rejection in solid organ transplantation, Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.

Who makes ATG+mycophénolate mofétil+tacrolimus?

ATG+mycophénolate mofétil+tacrolimus is developed and marketed by University Hospital, Toulouse (see full University Hospital, Toulouse pipeline at /company/university-hospital-toulouse).

Is ATG+mycophénolate mofétil+tacrolimus also known as anything else?

ATG+mycophénolate mofétil+tacrolimus is also known as Mycophénolate mofétil = Cellcept.

What drug class is ATG+mycophénolate mofétil+tacrolimus in?

ATG+mycophénolate mofétil+tacrolimus belongs to the Immunosuppressive combination therapy class. See all Immunosuppressive combination therapy drugs at /class/immunosuppressive-combination-therapy.

What development phase is ATG+mycophénolate mofétil+tacrolimus in?

ATG+mycophénolate mofétil+tacrolimus is FDA-approved (marketed).

What are the side effects of ATG+mycophénolate mofétil+tacrolimus?

Common side effects of ATG+mycophénolate mofétil+tacrolimus include Infection (bacterial, viral, fungal), Nephrotoxicity, Neurotoxicity (tremor, headache), Hyperglycemia, Hypertension, Gastrointestinal disturbances.

What does ATG+mycophénolate mofétil+tacrolimus target?

ATG+mycophénolate mofétil+tacrolimus targets T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus) and is a Immunosuppressive combination therapy.

Related